VIM and endometrial cancer: Interestingly, loss of vimentin was also highly significantly associated with poor recurrence-free survival when including all histologic types of endometrial cancers (Log rank p = 0.007; Fig. 8c) and in the subgroup of patients with endometrioid tumors (Log rank p = 0.005, data not shown).